Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
- 29 March 2013
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (16) , E1480-E1489
Abstract
Based on clinical presentation, glioblastoma (GBM) is stratified into primary and secondary types. The protein 53 (p53) pathway is functionally incapacitated in most GBMs by distinctive type-specific mechanisms. To model human gliomagenesis, we used a GFAP-HRasV12 mouse model crossed into the p53ERTAM background, such that either one or both copies of endogenous p53 is replaced by a conditional p53ERTAM allele. The p53ERTAM protein can be toggled reversibly in vivo between wild-type and inactive conformations by administration or withdrawal of 4-hydroxytamoxifen (4-OHT), respectively. Surprisingly, gliomas that develop in GFAP-HRasV12;p53+/KI mice abrogate the p53 pathway by mutating p19ARF/MDM2 while retaining wild-type p53 allele. Consequently, such tumors are unaffected by restoration of their p53ERTAM allele. By contrast, gliomas arising in GFAP-HRasV12;p53KI/KI mice develop in the absence of functional p53. Such tumors retain a functional p19ARF/MDM2-signaling pathway, and restoration of p53ERTAM allele triggers p53-tumor–suppressor activity. Congruently, growth inhibition upon normalization of mutant p53 by a small molecule, Prima-1, in human GBM cultures also requires p14ARF/MDM2 functionality. Notably, the antitumoral efficacy of p53 restoration in tumor-bearing GFAP-HRasV12;p53KI/KI animals depends on the duration and frequency of p53 restoration. Thus, intermittent exposure to p53ERTAM activity mitigated the selective pressure to inactivate the p19ARF/MDM2/p53 pathway as a means of resistance, extending progression-free survival. Our results suggest that intermittent dosing regimes of drugs that restore wild-type tumor-suppressor function onto mutant, inactive p53 proteins will prove to be more efficacious than traditional chronic dosing by similarly reducing adaptive resistance. Significance Glioblastoma is the most common and aggressive form of brain cancer. GBM patients typically respond poorly to conventional therapies. The tumor-suppressor protein 53 pathway is disrupted in a majority of GBM cases. Using a mouse model that mimics the progression of human GBM, we evaluate and optimize the therapeutic efficacy of functional p53 restoration in gliomas. We show that the efficacy of p53 restoration therapy in the animal model as well as in human GBM cells is improved markedly by an episodic dosing regimen that circumvents the selective pressure for adaptive resistance when p53 function is chronically restored.Keywords
This publication has 54 references indexed in Scilit:
- A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomasJournal of Experimental Medicine, 2011
- Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult BrainCancer Cell, 2011
- Selective activation of p53-mediated tumour suppression in high-grade tumoursNature, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Distinct Thresholds Govern Myc's Biological Output In VivoCancer Cell, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma modelProceedings of the National Academy of Sciences, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53The EMBO Journal, 1999